KPV: a tripeptide from α-MSH, and what “thin evidence” actually means

Three amino acids at the tail end of a larger hormone: a clear mechanistic idea and a deliberately narrow evidence base.

Peptalis: for laboratory research use only. Not for human use.

ARTICLE · IMMUNE & INFLAMMATORY · APPLICATIONS

Three amino acids at the tail end of a larger hormone, with a clear mechanistic idea and a deliberately narrow evidence base.

MVMichel van der VeenRegistered Nurse · Science Editor, Peptalis Sources checked via PubMed · 6 referencesReviewed August 2026 · 7 MIN READ In short
  • KPV stands for lysine-proline-valine: the last three amino acids of α-MSH.
  • The proposed point of action is NF-κB, a master switch for inflammatory genes.
  • Outside the test tube the evidence is narrow: one animal-model study, no human data.
  • Few studies is absence of evidence, not evidence of absence.

KPV is the smallest fragment of a much larger hormone. The name stands for the three amino acids lysine-proline-valine (Lys-Pro-Val) at the tail end of α-melanocyte-stimulating hormone (α-MSH). That hormone has been known for decades as a substance acting on both the nervous system and the immune system, and able to damp inflammation (Ichiyama et al., 2000, PMID 11268347, review). The question that makes KPV interesting is simple: does that smallest fragment carry the same inflammation-damping property?

3amino acids: Lys-Pro-Valα-MSH(11–13)position in the parent hormone1animal-model study in the curated set

The proposed mechanism is clear

In cells, KPV limits the switching-on of NF-κB, a kind of master switch that turns on countless inflammatory genes at once. Open that switch less far and the inflammatory response gets less traction. In macrophage-like cells (RAW 264.7) a melanocortin peptide reduced exactly that switch activity and the production of nitric oxide, an inflammatory substance (Mandrika et al., 2001, PMID 11239505, in vitro), and a related tripeptide softened the same NF-κB response after an inflammatory stimulus (Haddad et al., 2001, PMID 11256945, in vitro). Together those studies give a consistent picture in the test tube: the point of action is the NF-κB route.

From α-MSH to three amino acids · point of action: the NF-κB route Everything here comes from cell work plus one animal model. No human data; no dose-response characterisation.

Outside the test tube the evidence is narrow

The most concrete animal-model study showed that a single administration of the α-MSH(11–13) tripeptide reduced brain damage through less inflammation and apoptosis after experimental traumatic brain injury in mice (Schaible et al., 2013, PMID 23940690, animal model). That is exactly one animal model: no series, no replication across several groups, and no human data. Alongside it there is exploratory work in skin cells: α-MSH, KPV and ACTH signalling in human keratinocytes (Elliott et al., 2004, PMID 15102092, in vitro).

Why “thin” is not a disqualification here

That KPV has been little studied is not the same as evidence that it does nothing. It is absence of evidence, not evidence of absence. Short peptides like this one are commercially unattractive to develop clinically: they are hard to patent and human research is expensive. Precisely for that reason a mechanistically clear, patent-free fragment such as KPV stays untouched. For laboratories working on inflammatory signalling that is an opening rather than a shortcoming: the NF-κB hypothesis is testable, and the step from in vitro to careful animal models is largely still untaken.

What is missing

Independent replication of the animal-model finding, multiple models, and systematic dose-response characterisation. Until those exist, KPV remains an interesting starting point for further research: no more than that, and that is exactly what the evidence status honestly reflects.

What this does say
  • ✓Studies describe inhibition of NF-κB activity in cell lines.
  • ✓One animal-model study reports less inflammation and apoptosis after experimental brain injury.
What it does not say
  • ✕No study demonstrates an effect in humans.
  • ✕No finding supports treatment of any condition.
About the authorMVMichel van der VeenRegistered Nurse · Science Editor, Peptalis

Registered nurse with eleven years in psychiatry and founder of Peptalis. Writes the platform's knowledge layer: compound profiles, evidence reviews and the quality methodology. Works from primary literature (PubChem for chemistry, PubMed for studies) and states where evidence is absent.

Sources checked via PubMed · 6 references

Compound profilesEvidence reviewsQualityIN THIS ARTICLE
  • The proposed mechanism is clear
  • Outside the test tube the evidence is narrow
  • Why “thin” is not a disqualification here
  • What is missing
SCIENTIFIC REFERENCESView all references →RELATED COMPOUNDKPV →RELATED ARTICLES

Compounds in this article

For laboratory research use only. Not for human use.

SCIENTIFIC REFERENCES

These references are provided for informational and research purposes only. They do not constitute medical advice.

  1. 01In vitroAntimicrobial effects of alpha-MSH peptides.Cutuli M, Cristiani S, Lipton JM, Catania A. J Leukoc Biol. 2000;67(2):233–239.View on PubMed →
  2. 02ReviewAnti-inflammatory effects of alpha-melanocyte-stimulating hormone.Ichiyama T, Sakai T, Catania A, et al. Ann N Y Acad Sci. 2000;917:221–226.Overview of the parent hormone: where α-MSH acts and why it is described as damping inflammation.View on PubMed →
  3. 03In vitroMelanocortin peptides inhibit NF-κB activation and nitric oxide production in RAW 264.7 cells.Mandrika I, Muceniece R, Wikberg JE. Biochem Pharmacol. 2001;61(5):613–621.Test-tube work in macrophage-like cells; the point of action is the NF-κB route.View on PubMed →
  4. 04In vitroAlpha-melanocyte-related tripeptide suppresses the NF-κB response to an inflammatory stimulus.Haddad JJ, Lauterbach R, Saadé NE, et al. Biochem J. 2001;355(Pt 1):29–38.View on PubMed →
  5. 05In vitroAlpha-MSH, KPV and ACTH signalling in human keratinocytes.Elliott RJ, Szabo M, Wagner MJ, et al. J Invest Dermatol. 2004;122(4):1010–1019.Exploratory work in skin cells; descriptive, with no outcome measure.View on PubMed →
  6. 06Animal modelSingle administration of tripeptide α-MSH(11–13) attenuates brain damage after controlled cortical impact in mice.Schaible EV, Steinsträßer A, Jahn-Eimermacher A, et al. PLoS One. 2013;8(8):e71056.Exactly one animal model: no series, no replication, no human data.View on PubMed →

Peptalis is a knowledge platform. All content on this page is provided for scientific and educational reference purposes only and does not constitute medical advice. Compounds discussed are research compounds and are not intended for human or veterinary use.